Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan

Autor: Sleutjes, Boudewijn T.H.M., Bystrup Jacobsen, Anna, Tankisi, Hatice, Gorkem Sirin, N., Emre Oge, A., Henderson, Robert D., van Doorn, Pieter A., van den Berg, Leonard H., van Eijk, Ruben P.A.

Publikováno v: In Clinical Neurophysiology December 2021 132(12):3152-3159

Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial.

Autor: Willemse, Sean W.¹ (AUTHOR), Roes, Kit C. B.² (AUTHOR), Van Damme, Philip³ (AUTHOR), Hardiman, Orla^4,5 (AUTHOR), Ingre, Caroline⁶ (AUTHOR), Povedano, Monica⁷ (AUTHOR), Wray, Naomi R.⁸ (AUTHOR), Gijzen, Marleen⁹ (AUTHOR), de Pagter, Mirjam S.⁹ (AUTHOR), Demaegd, Koen C.¹ (AUTHOR), Janse, Annemarie F. C.¹⁰ (AUTHOR), Vink, Roel G.¹⁰ (AUTHOR), Sleutjes, Boudewijn T. H. M.¹ (AUTHOR), Chiò, Adriano^11,12 (AUTHOR), Corcia, Philippe¹³ (AUTHOR), Reviers, Evy¹⁴ (AUTHOR), Al-Chalabi, Ammar^15,16 (AUTHOR), Kiernan, Matthew C.^17,18 (AUTHOR), van den Berg, Leonard H.¹ (AUTHOR), van Es, Michael A.¹ (AUTHOR)

Publikováno v: Trials. 12/5/2022, Vol. 23 Issue 1, p1-18. 18p. 2 Charts.

Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan

Autor: Hatice Tankisi, Pieter A. van Doorn, Robert D. Henderson, Leonard H. van den Berg, Ruben P A van Eijk, Boudewijn T.H.M. Sleutjes, A. Emre Öge, A.B. Jacobsen, N. Gorkem Sirin

Publikováno v: Sleutjes, B T H M, Bystrup Jacobsen, A, Tankisi, H, Gorkem Sirin, N, Emre Oge, A, Henderson, R D, van Doorn, P A, van den Berg, L H & van Eijk, R P A 2021, ' Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan ', Clinical Neurophysiology, vol. 132, no. 12, pp. 3152-3159 . https://doi.org/10.1016/j.clinph.2021.09.014
Clinical Neurophysiology, 132(12), 3152-3159. Elsevier Ireland Ltd

Objective To determine which compound muscle action potential (CMAP) scan-derived electrophysiological markers are most sensitive for monitoring disease progression in amyotrophic lateral sclerosis (ALS), and whether they hold value for clinical tria

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40178af5a0dbaacefd34fafd53e0debc
https://doi.org/10.1016/j.clinph.2021.09.014